Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2017 May 15;27(10):2216-2220. doi: 10.1016/j.bmcl.2017.03.030. Epub 2017 Mar 18.

Novel small molecule guanidine Sigma1 inhibitors for advanced prostate cancer.

Author information

1
Department of Pharmacology and Physiology, Drexel University College of Medicine, 245 N 15th Street, Philadelphia, PA 19102-1101, USA. Electronic address: jsalvino@wistar.org.
2
Department of Pharmacology and Physiology, Drexel University College of Medicine, 245 N 15th Street, Philadelphia, PA 19102-1101, USA.
3
AstaTech, Inc., Keystone Business Park, 2525 Pearl Buck Road, Bristol, PA 19007, USA.

Abstract

Prostate cancer is the most frequently diagnosed malignancy and the leading cause of cancer related death in men. First line therapy for disseminated disease relies on androgen deprivation, leveraging the addiction of these tumors on androgens for both growth and survival. Treatment typically involves antagonizing the androgen receptor (AR) or blocking the synthesis of androgens. Recurrence is common and within 2-3years patients develop castration resistant tumors that become unresponsive to AR-axis targeted therapies. In order to provide a more effective treatment, we are utilizing an approach that targets a key scaffolding protein, Sigma1 (also known as sigma-1 receptor), a unique 26-kilodalton integral membrane protein that is critical in stabilizing the AR. Herein we report on a new series of Sigma1 compounds for lead optimization derived from a hybrid pharmacophore approach.

KEYWORDS:

Guanidine; Prostate cancer; Sigma-1 chaperone; Sigma-1 receptor; Sigma1; Small molecule inhibitor

PMID:
28385503
PMCID:
PMC5714280
DOI:
10.1016/j.bmcl.2017.03.030
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center